Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 46 entries
Sorted by: Best Match Show Resources per page
Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study.

Clinical & translational immunology

Johnson KH, Webb CH, Schmeling DO, Brundage RC, Balfour HH.
PMID: 27350880
Clin Transl Immunology. 2016 May 13;5(5):e81. doi: 10.1038/cti.2016.28. eCollection 2016 May.

Characterizing Epstein-Barr virus (EBV) dynamics in asymptomatic immunocompetent persons provides a baseline for defining quantitative thresholds associated with EBV disease. Studying latent membrane protein (LMP)-1 sequence variation over time could establish the rates of reactivation and superinfection, and also...

Cite
Johnson KH, Webb CH, Schmeling DO, et al. Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clin Transl Immunology. 2016;5(5):e81doi: 10.1038/cti.2016.28.
Johnson, K. H., Webb, C. H., Schmeling, D. O., Brundage, R. C., & Balfour, H. H. (2016). Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clinical & translational immunology, 5(5), e81. https://doi.org/10.1038/cti.2016.28
Johnson, Kristin H, et al. "Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study." Clinical & translational immunology vol. 5,5 (2016): e81. doi: https://doi.org/10.1038/cti.2016.28
Johnson KH, Webb CH, Schmeling DO, Brundage RC, Balfour HH. Epstein-Barr virus dynamics in asymptomatic immunocompetent adults: an intensive 6-month study. Clin Transl Immunology. 2016 May 13;5(5):e81. doi: 10.1038/cti.2016.28. eCollection 2016 May. PMID: 27350880; PMCID: PMC4910122.
Copy Download .nbib Format: NLM
Osculatory packing of finite areas with circles.

Nature

Kausch-Blecken HH, Schmeling V, Tschoegl NW.
PMID: 16056952
Nature. 1970 Mar 21;225(5238):1119-22. doi: 10.1038/2251119a0.

Osculatory packing of a finite area by circles requires that any uncovered area or interstice be filled always with the largest possible non-overlapping circle. The strength of this requirement makes it possible to derive a general analytic expression that...

Cite
Kausch-Blecken HH, Schmeling V, Tschoegl NW. Osculatory packing of finite areas with circles. Nature. 1970;225(5238):1119-22doi: 10.1038/2251119a0.
Kausch-Blecken, H. H., Schmeling, V., & Tschoegl, N. W. (1970). Osculatory packing of finite areas with circles. Nature, 225(5238), 1119-22. https://doi.org/10.1038/2251119a0
Kausch-Blecken, H H, et al. "Osculatory packing of finite areas with circles." Nature vol. 225,5238 (1970): 1119-22. doi: https://doi.org/10.1038/2251119a0
Kausch-Blecken HH, Schmeling V, Tschoegl NW. Osculatory packing of finite areas with circles. Nature. 1970 Mar 21;225(5238):1119-22. doi: 10.1038/2251119a0. PMID: 16056952.
Copy Download .nbib Format: NLM
Systemic fungicidal activity of 1,4-oxathiin derivatives.

Science (New York, N.Y.)

Schmeling BV, Kulka M.
PMID: 17779512
Science. 1966 Apr 29;152(3722):659-60. doi: 10.1126/science.152.3722.659.

Treatment of pinto bean and barley seed with 1,4-oxathiin derivatives gave disease control by systemic fungicidal action of such pathogenic fungi as Uromyces phaseoli and Ustilago nuda. The two chemicals, D735 and F461, were highly specific and selective against...

Cite
Schmeling BV, Kulka M. Systemic fungicidal activity of 1,4-oxathiin derivatives. Science. 1966;152(3722):659-60doi: 10.1126/science.152.3722.659.
Schmeling, B. V., & Kulka, M. (1966). Systemic fungicidal activity of 1,4-oxathiin derivatives. Science (New York, N.Y.), 152(3722), 659-60. https://doi.org/10.1126/science.152.3722.659
Schmeling, B V, and Kulka, M. "Systemic fungicidal activity of 1,4-oxathiin derivatives." Science (New York, N.Y.) vol. 152,3722 (1966): 659-60. doi: https://doi.org/10.1126/science.152.3722.659
Schmeling BV, Kulka M. Systemic fungicidal activity of 1,4-oxathiin derivatives. Science. 1966 Apr 29;152(3722):659-60. doi: 10.1126/science.152.3722.659. PMID: 17779512.
Copy Download .nbib Format: NLM
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.

Rheumatology (Oxford, England)

Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ.
PMID: 33493312
Rheumatology (Oxford). 2021 Oct 02;60(10):4495-4507. doi: 10.1093/rheumatology/keab021.

OBJECTIVES: To assess efficacy, pharmacokinetics (PK) and safety of intravenous (i.v.) golimumab in patients with polyarticular-course JIA (pc-JIA).METHODS: Children aged 2 to

Cite
Ruperto N, Brunner HI, Pacheco-Tena C, et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60(10):4495-4507doi: 10.1093/rheumatology/keab021.
Ruperto, N., Brunner, H. I., Pacheco-Tena, C., Louw, I., Vega-Cornejo, G., Spindler, A. J., Kingsbury, D. J., Schmeling, H., Borzutzky, A., Cuttica, R., Inman, C. J., Malievskiy, V., Scott, C., Keltsev, V., Terreri, M. T., Viola, D. O., Xavier, R. M., Fernandes, T. A. P., Velázquez, M. D. R. M., Henrickson, M., Clark, M. B., Bensley, K. A., Li, X., Lo, K. H., Leu, J. H., Hsu, C. H., Hsia, E. C., Xu, Z., Martini, A., Lovell, D. J. (2021). Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford, England), 60(10), 4495-4507. https://doi.org/10.1093/rheumatology/keab021
Ruperto, Nicolino, et al. "Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis." Rheumatology (Oxford, England) vol. 60,10 (2021): 4495-4507. doi: https://doi.org/10.1093/rheumatology/keab021
Ruperto N, Brunner HI, Pacheco-Tena C, Louw I, Vega-Cornejo G, Spindler AJ, Kingsbury DJ, Schmeling H, Borzutzky A, Cuttica R, Inman CJ, Malievskiy V, Scott C, Keltsev V, Terreri MT, Viola DO, Xavier RM, Fernandes TAP, Velázquez MDRM, Henrickson M, Clark MB, Bensley KA, Li X, Lo KH, Leu JH, Hsu CH, Hsia EC, Xu Z, Martini A, Lovell DJ. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 02;60(10):4495-4507. doi: 10.1093/rheumatology/keab021. PMID: 33493312; PMCID: PMC8487314.
Copy Download .nbib Format: NLM
Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis.

ACR open rheumatology

Chomistek K, Barnabe C, Naqvi SF, Birnie KA, Johnson N, Luca N, Miettunen P, Santana MJ, Stinson J, Schmeling H.
PMID: 34791829
ACR Open Rheumatol. 2021 Nov 17; doi: 10.1002/acr2.11373. Epub 2021 Nov 17.

OBJECTIVE: The study objective was to test the acceptability of a self-management program (SMP) for adolescents with juvenile idiopathic arthritis (JIA) focused on disease information, self-management, and social support needs.METHODS: This study was conducted using inductive qualitative methods to...

Cite
Chomistek K, Barnabe C, Naqvi SF, et al. Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis. ACR Open Rheumatol. 2021;doi: 10.1002/acr2.11373.
Chomistek, K., Barnabe, C., Naqvi, S. F., Birnie, K. A., Johnson, N., Luca, N., Miettunen, P., Santana, M. J., Stinson, J., & Schmeling, H. (2021). Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis. ACR open rheumatology, . https://doi.org/10.1002/acr2.11373
Chomistek, Kelsey, et al. "Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis." ACR open rheumatology vol. (2021). doi: https://doi.org/10.1002/acr2.11373
Chomistek K, Barnabe C, Naqvi SF, Birnie KA, Johnson N, Luca N, Miettunen P, Santana MJ, Stinson J, Schmeling H. Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis. ACR Open Rheumatol. 2021 Nov 17; doi: 10.1002/acr2.11373. Epub 2021 Nov 17. PMID: 34791829.
Copy Download .nbib Format: NLM
The multifaceted eukaryotic cap structure.

Wiley interdisciplinary reviews. RNA

Pelletier J, Schmeing TM, Sonenberg N.
PMID: 33300197
Wiley Interdiscip Rev RNA. 2021 Mar;12(2):e1636. doi: 10.1002/wrna.1636. Epub 2020 Dec 09.

The 5' cap structure is added onto RNA polymerase II transcripts soon after initiation of transcription and modulates several post-transcriptional regulatory events involved in RNA maturation. It is also required for stimulating translation initiation of many cytoplasmic mRNAs and...

Cite
Pelletier J, Schmeing TM, Sonenberg N. The multifaceted eukaryotic cap structure. Wiley Interdiscip Rev RNA. 2020;12(2):e1636doi: 10.1002/wrna.1636.
Pelletier, J., Schmeing, T. M., & Sonenberg, N. (2021). The multifaceted eukaryotic cap structure. Wiley interdisciplinary reviews. RNA, 12(2), e1636. https://doi.org/10.1002/wrna.1636
Pelletier, Jerry, et al. "The multifaceted eukaryotic cap structure." Wiley interdisciplinary reviews. RNA vol. 12,2 (2021): e1636. doi: https://doi.org/10.1002/wrna.1636
Pelletier J, Schmeing TM, Sonenberg N. The multifaceted eukaryotic cap structure. Wiley Interdiscip Rev RNA. 2021 Mar;12(2):e1636. doi: 10.1002/wrna.1636. Epub 2020 Dec 09. PMID: 33300197.
Copy Download .nbib Format: NLM
Publisher Correction: Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1.

Scientific reports

Layoun A, Goldberg AA, Baig A, Eng M, Attias O, Nelson K, Carella A, Amberber N, Fielhaber JA, Joung KB, Schmeing TM, Han Y, Downey J, Divangahi M, Roux PP, Kristof AS.
PMID: 32075988
Sci Rep. 2020 Feb 19;10(1):3337. doi: 10.1038/s41598-020-58962-z.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Layoun A, Goldberg AA, Baig A, et al. Publisher Correction: Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1. Sci Rep. 2020;10(1):3337doi: 10.1038/s41598-020-58962-z.
Layoun, A., Goldberg, A. A., Baig, A., Eng, M., Attias, O., Nelson, K., Carella, A., Amberber, N., Fielhaber, J. A., Joung, K. B., Schmeing, T. M., Han, Y., Downey, J., Divangahi, M., Roux, P. P., & Kristof, A. S. (2020). Publisher Correction: Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1. Scientific reports, 10(1), 3337. https://doi.org/10.1038/s41598-020-58962-z
Layoun, Antonio, et al. "Publisher Correction: Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1." Scientific reports vol. 10,1 (2020): 3337. doi: https://doi.org/10.1038/s41598-020-58962-z
Layoun A, Goldberg AA, Baig A, Eng M, Attias O, Nelson K, Carella A, Amberber N, Fielhaber JA, Joung KB, Schmeing TM, Han Y, Downey J, Divangahi M, Roux PP, Kristof AS. Publisher Correction: Regulation of protein kinase Cδ Nuclear Import and Apoptosis by Mechanistic Target of Rapamycin Complex-1. Sci Rep. 2020 Feb 19;10(1):3337. doi: 10.1038/s41598-020-58962-z. PMID: 32075988; PMCID: PMC7031502.
Copy Download .nbib Format: NLM
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.

Rheumatology (Oxford, England)

Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F.
PMID: 33506875
Rheumatology (Oxford). 2021 Oct 02;60(10):4568-4580. doi: 10.1093/rheumatology/keab047.

OBJECTIVES: To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA).METHODS: In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (every 10...

Cite
Ruperto N, Brunner HI, Ramanan AV, et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021;60(10):4568-4580doi: 10.1093/rheumatology/keab047.
Ruperto, N., Brunner, H. I., Ramanan, A. V., Horneff, G., Cuttica, R., Henrickson, M., Anton, J., Boteanu, A. L., Penades, I. C., Minden, K., Schmeling, H., Hufnagel, M., Weiss, J. E., Pardeo, M., Nanda, K., Roth, J., Rubio-Pérez, N., Hsu, J. C., Wimalasundera, S., Wells, C., Bharucha, K., Douglass, W., Bao, M., Mallalieu, N. L., Martini, A., Lovell, D., Benedetti, F. (2021). Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford, England), 60(10), 4568-4580. https://doi.org/10.1093/rheumatology/keab047
Ruperto, Nicolino, et al. "Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis." Rheumatology (Oxford, England) vol. 60,10 (2021): 4568-4580. doi: https://doi.org/10.1093/rheumatology/keab047
Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology (Oxford). 2021 Oct 02;60(10):4568-4580. doi: 10.1093/rheumatology/keab047. PMID: 33506875; PMCID: PMC8487273.
Copy Download .nbib Format: NLM
Fate and Transport of Shale-derived, Biogenic Methane.

Scientific reports

Hendry MJ, Schmeling EE, Barbour SL, Huang M, Mundle SOC.
PMID: 28687757
Sci Rep. 2017 Jul 07;7(1):4881. doi: 10.1038/s41598-017-05103-8.

Natural gas extraction from unconventional shale gas reservoirs is the subject of considerable public debate, with a key concern being the impact of leaking fugitive natural gases on shallow potable groundwater resources. Baseline data regarding the distribution, fate, and...

Cite
Hendry MJ, Schmeling EE, Barbour SL, et al. Fate and Transport of Shale-derived, Biogenic Methane. Sci Rep. 2017;7(1):4881doi: 10.1038/s41598-017-05103-8.
Hendry, M. J., Schmeling, E. E., Barbour, S. L., Huang, M., & Mundle, S. O. C. (2017). Fate and Transport of Shale-derived, Biogenic Methane. Scientific reports, 7(1), 4881. https://doi.org/10.1038/s41598-017-05103-8
Hendry, M Jim, et al. "Fate and Transport of Shale-derived, Biogenic Methane." Scientific reports vol. 7,1 (2017): 4881. doi: https://doi.org/10.1038/s41598-017-05103-8
Hendry MJ, Schmeling EE, Barbour SL, Huang M, Mundle SOC. Fate and Transport of Shale-derived, Biogenic Methane. Sci Rep. 2017 Jul 07;7(1):4881. doi: 10.1038/s41598-017-05103-8. PMID: 28687757; PMCID: PMC5501783.
Copy Download .nbib Format: NLM
Disability as diversity in Fortune 100 companies.

Behavioral sciences & the law

Ball P, Monaco G, Schmeling J, Schartz H, Blanck P.
PMID: 15706604
Behav Sci Law. 2005;23(1):97-121. doi: 10.1002/bsl.629.

To investigate the inclusion of people with disabilities in the diversity policies of the most successful businesses in the United States, we examined the publicly available workforce and supplier diversity policies of the top 100 companies on Fortune Magazine's...

Cite
Ball P, Monaco G, Schmeling J, et al. Disability as diversity in Fortune 100 companies. Behav Sci Law. 2005;23(1):97-121doi: 10.1002/bsl.629.
Ball, P., Monaco, G., Schmeling, J., Schartz, H., & Blanck, P. (2005). Disability as diversity in Fortune 100 companies. Behavioral sciences & the law, 23(1), 97-121. https://doi.org/10.1002/bsl.629
Ball, Phoebe, et al. "Disability as diversity in Fortune 100 companies." Behavioral sciences & the law vol. 23,1 (2005): 97-121. doi: https://doi.org/10.1002/bsl.629
Ball P, Monaco G, Schmeling J, Schartz H, Blanck P. Disability as diversity in Fortune 100 companies. Behav Sci Law. 2005;23(1):97-121. doi: 10.1002/bsl.629. PMID: 15706604.
Copy Download .nbib Format: NLM
Functionalized copolyimide membranes for the separation of gaseous and liquid mixtures.

Beilstein journal of organic chemistry

Schmeling N, Konietzny R, Sieffert D, Rölling P, Staudt C.
PMID: 20978620
Beilstein J Org Chem. 2010 Aug 12;6:789-800. doi: 10.3762/bjoc.6.86.

Functionalized copolyimides continue to attract much attention as membrane materials because they can fulfill the demands for industrial applications. Thus not only good separation characteristics but also high temperature stability and chemical resistance are required. Furthermore, it is very...

Cite
Schmeling N, Konietzny R, Sieffert D, et al. Functionalized copolyimide membranes for the separation of gaseous and liquid mixtures. Beilstein J Org Chem. 2010;6:789-800doi: 10.3762/bjoc.6.86.
Schmeling, N., Konietzny, R., Sieffert, D., Rölling, P., & Staudt, C. (2010). Functionalized copolyimide membranes for the separation of gaseous and liquid mixtures. Beilstein journal of organic chemistry, 6789-800. https://doi.org/10.3762/bjoc.6.86
Schmeling, Nadine, et al. "Functionalized copolyimide membranes for the separation of gaseous and liquid mixtures." Beilstein journal of organic chemistry vol. 6 (2010): 789-800. doi: https://doi.org/10.3762/bjoc.6.86
Schmeling N, Konietzny R, Sieffert D, Rölling P, Staudt C. Functionalized copolyimide membranes for the separation of gaseous and liquid mixtures. Beilstein J Org Chem. 2010 Aug 12;6:789-800. doi: 10.3762/bjoc.6.86. PMID: 20978620; PMCID: PMC2956472.
Copy Download .nbib Format: NLM
Pesticide, PCB, and lead residues and necropsy data for bald eagles from 32 states-1978-81.

Environmental monitoring and assessment

Reichel WL, Schmeling SK, Cromartie E, Kaiser TE, Krynitsky AJ, Lamont TG, Mulhern BM, Prouty RM, Stafford CJ, Swineford DM.
PMID: 24257866
Environ Monit Assess. 1984 Dec;4(4):395-403. doi: 10.1007/BF00394177.

In 1978-81, 293 bald eagles (Haliaeetus leucocephalus) from 32 states were necropsied and analyzed for organochlorine pesticides, polychlorinated biphenyls (PCB), and lead residues. DDE was found in all carcasses; PCB, DDD, trans-nonachlor, dieldrin and oxychlordane were next in order...

Cite
Reichel WL, Schmeling SK, Cromartie E, et al. Pesticide, PCB, and lead residues and necropsy data for bald eagles from 32 states-1978-81. Environ Monit Assess. 1984;4(4):395-403doi: 10.1007/BF00394177.
Reichel, W. L., Schmeling, S. K., Cromartie, E., Kaiser, T. E., Krynitsky, A. J., Lamont, T. G., Mulhern, B. M., Prouty, R. M., Stafford, C. J., & Swineford, D. M. (1984). Pesticide, PCB, and lead residues and necropsy data for bald eagles from 32 states-1978-81. Environmental monitoring and assessment, 4(4), 395-403. https://doi.org/10.1007/BF00394177
Reichel, W L, et al. "Pesticide, PCB, and lead residues and necropsy data for bald eagles from 32 states-1978-81." Environmental monitoring and assessment vol. 4,4 (1984): 395-403. doi: https://doi.org/10.1007/BF00394177
Reichel WL, Schmeling SK, Cromartie E, Kaiser TE, Krynitsky AJ, Lamont TG, Mulhern BM, Prouty RM, Stafford CJ, Swineford DM. Pesticide, PCB, and lead residues and necropsy data for bald eagles from 32 states-1978-81. Environ Monit Assess. 1984 Dec;4(4):395-403. doi: 10.1007/BF00394177. PMID: 24257866.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 46 entries